Personal Healthcare Budgets: Sheffield

Lord Blunkett Excerpts

Wednesday 4th September 2019 Lords Chamber

Asked by

[Lord Blunkett]

To ask Her Majesty’s Government what was the difference in the number of people covered by personal health care budgets or Independent Living Fund payments in Sheffield between (1) January and June 2019, (2) January and June 2018, (3) January and June 2017, and (4) January and June 2015.

[The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Blackwood of North Oxford) (Con)]

My Lords, the department does not collect the data requested in the specified format. However, the number of people with a personalised health budget is calculated on a quarterly basis within each financial year, which ends on 31 March. Currently, 53,143 people benefit from a personal health budget nationally. I shall write to the noble Lord this afternoon with a full breakdown of all the data that we collect in relation to Sheffield and place a copy of the letter in the Library.

[Lord Blunkett (Lab)]

I am grateful to the Minister. Can she help me with a very practical question relating to the county council’s publication last week, and that of the Institute for Government today, in respect of the funding of social and the interim grant that was due to run out at the end of March next year, which constituted a third of government spending? Can we presume that the amount announced by the Chancellor of the Exchequer this afternoon is in addition to renewing that temporary grant? If it is, is it not a strange paradox that it is half a billion pounds less than the amount that he announced in respect of a no-deal arrangement with the European Union?

[Baroness Blackwood of North Oxford]

The noble Lord has asked a very important question and I am pleased that the Prime Minister has followed through on his commitment to improve the situation for local authorities and for social care, not only by increasing funding for social care by £1 billion today but by increasing funding for local authorities. This is a welcome change for local authorities, which need to ensure that they can fund the commitments that we have. In addition to the letter that I shall place in the Library, I shall be happy to follow up on the specific challenge that the noble Lord raised regarding Sheffield following Questions.

Cannabis-based Medicines

Lord Blunkett Excerpts

Thursday 21st June 2018 Lords Chamber

[Lord O’Shaughnessy]

The noble Baroness makes excellent points. I know she has been deeply involved in the Alfie Dingley case and I thank her for her work on that. What we are discovering is that it is not the case that just one drug is going to fix this for the 200,000 people who are suffering. There is a need for variety. So it cannot be the case that just because one thing is licensed it is used for everyone; it needs to be specific to the needs of the patient, which is the noble Baroness’s main point. The interim panel is there precisely to make decisions on an individual basis. It is a patch to the system, if you like, not a long-term change, which is why the review is in place so that we can ensure that many other products derived from cannabis, if they are proven to have therapeutic benefits, can be developed into drugs for the range of needs that are out there.

[Lord Blunkett (Lab)]

My Lords, 15 years ago trials were undertaken, one of which led to a separate authorisation of a derivative from cannabis for MS sufferers. I have not been clear on this from any of the reporting, so will the Minister say what trials are currently taking place in this country that could be brought to fruition? What evidence can we very quickly obtain from trials and evidence of legitimate use for medicinal purposes from the rest of the democratic world? How can it possibly be justifiable for us to provide 45% of usage for derivatives from cannabis grown in this country but not to be able to use it ourselves?

[Lord O’Shaughnessy]

The noble Lord speaks with great wisdom on this topic. The problem, as he knows, is that these drugs have been in Schedule 1 and, although in theory that allows for research, in reality it creates a very cautious environment that makes research difficult. That means that apart from Sativex, which has been licensed, and Epidiolex, which is in the process of being licensed, there are very few, if any, other drugs actually going through the clinical trials process in this country because of the very tight rules that have governed usage. Other countries have of course relaxed their rules and developed that evidence, and it is precisely that kind of evidence base that will be considered by Professor Davies in her review.

Chronic Lymphocytic Leukaemia: Ibrutinib

Lord Blunkett Excerpts

Thursday 7th June 2018 Lords Chamber

[Lord O'Shaughnessy]

I thank the right reverend Prelate for that question. As he will know, NICE consults widely with patient groups and others in making its decisions. I am not clear at this stage whether NHS England met patient groups and others in designing its clinical commissioning guidelines, which is of course what I shall investigate next week.

[Lord Blunkett (Lab)]

First, I commend the Minister for being prepared to come to the noble Baroness Jowell’s funeral last week, which was greatly appreciated. Secondly, I commend him for his obvious commitment and detailed understanding on this particular issue that has been raised this morning. Is it not exactly the same issue as Baroness Jowell was raising, although on a very different treatment and challenge, which is that the best and most appropriate treatment should be available as quickly and easily as possible everywhere and to everyone, wherever they live?

[Lord O'Shaughnessy]

I am grateful to the noble Lord for that. I was privileged to be invited to the funeral, which was a very moving occasion for a very special lady. On his overall point, NICE approves 71% of cancer drugs that are applied for, so there is an absolute focus on making sure that the most effective cancer drugs can be brought to patients in England as soon as possible. Under the reformed cancer drugs fund, that can now happen from the point at which there is a draft guideline, which is often many months before it would otherwise be the case. That means that tens of thousands of people have been able to access cancer drugs earlier than they would ever have done before and, as a consequence, many lives have been saved.

Children: Obesity

Lord Blunkett Excerpts

Thursday 10th May 2018 Lords Chamber

[Lord O'Shaughnessy]

It goes to show that public health campaigns can be effective. I remember the “Go to work on an egg” campaign—although I had a banana myself. The serious point is that too many children do not go to school after a proper breakfast, and one of the great advances with the sugar levy has been a commitment of around £26 million to support breakfast clubs in about 1,500 schools in areas that unfortunately have the worst outcomes for healthy children and obesity. That support will help those children go to school on a good breakfast and function properly.

[Lord Blunkett (Lab)]

Does the Minister agree that one of the tragedies of the demise of so many Sure Start programmes was that parents were engaged in not just nurturing but understanding what happened to their children, particularly in poor areas where junk food was bought as opposed to learning to cook? Will he put some emphasis on parents being taught how to cook nutritious food, and not just children?

[Lord O'Shaughnessy]

I could not agree with the noble Lord more about the importance of good parenting and parents setting an example in this area. I would focus on a major Public Health England initiative, Change4Life, which is about equipping parents with the knowledge and understanding of how to prepare good-quality, healthy meals that are affordable.

Children: Obesity

Lord Blunkett Excerpts

Thursday 19th April 2018 Lords Chamber

[Lord O’Shaughnessy]

Following the debate that we had the other day, I looked up the Daily Mile online. It is now in 2,000 schools across the UK. My right honourable friend the Secretary of State has described it as an excellent initiative, which indeed it looks like. It certainly seems to develop good habits of physical and mental health. Writing to schools is of course a matter for the Department for Education, but I will certainly speak to my colleagues in that department to encourage schools to take this up. In the spirit of the debate of the noble Baroness, Lady Walmsley, I think it would be better to end with a quote from William at Woodfield Primary School in Wigan, who said that the Daily Mile,

“helps you with your maths, English, and you get faster each time, which makes you healthier”.

What more could you want?

[Lord Blunkett (Lab)]

My Lords, I cannot match the alliteration of the Minister but I ask him if he and his colleagues in other departments would consider an addition to the sport, to the dietary and to the drive against sugar, given the evidence of the recent review that the Government undertook into full-time social youth action in which organisations such as Volunteering Matters and City Year UK demonstrate that work by young people for young people against bullying, emotional trauma and mental health problems can have a real effect.

[Lord O'Shaughnessy]

I completely agree with the noble Lord. I believe that he chairs the National Citizen Service, which has been a massive initiative to encourage such habits in teenagers. I completely concur with him: the Government take a number of approaches to encourage youth social action, and that is something that we will continue to support.

NHS: Cancer Treatments

Lord Blunkett Excerpts

Thursday 25th January 2018 Lords Chamber

[Lord Blunkett (Lab)]

My Lords, this is the greatest privilege, and one of the most daunting moments of my life—to follow my noble friend, with the eloquence, the care, the compassion and the courage she has shown. She is my noble friend—not by affiliation or values, although we share them—but through a lifelong friendship that has lasted for well over 40 years.

If the House will forgive me, I want to say a word about Tessa—the noble Baroness, Lady Jowell—as a person. We got to know each other when we both chaired our respective social services committee. That is when I saw to begin with her care and compassion, described so well this afternoon. It is a compassion that has overcome the challenges that she faces and those of her family. Yesterday on the “Today” programme, and she said it this afternoon about the community of care, it was not just her own courage that shone through; it was the deep love and affection of her family—David, Jess and Matthew, and her extended family. The care she displayed this afternoon reached out, because it is the caring family and the community around those with cancer who travel on the journey as well. It is the love and hope that they give that reaches out.

Sally, the young mother on the “Today” programme yesterday, as with the experience of the noble Baroness, Lady Rebuck, whose husband Philip I knew well and saw just three days before he died, displayed the search for excellence, for innovation and, above all, for action, that my noble friend has called for this afternoon.

I know absolutely nothing about the ECI—but I will. There is a need to set aside bureaucracy in terms of the experimentation that patients who are on this journey wish to try, to set aside the usual processes and to share the best practice from wherever it comes. Part of the role of family is to enable people to be able to sustain themselves while they seek access to that innovation and that improvement, and to know about where excellence exists here and across the world. Who you know is so often—too often—the telling point when you are seeking the best that exists in scientific development. What my noble friend Lady Jowell, my friend Tessa, has said this afternoon is that this should be available whoever you know, wherever you are and whatever access you have had to other people’s knowledge. The breakthroughs across the world need to be made available as quickly and with as little bureaucracy in our health service as possible.

My noble friend mentioned 24 May last year, when she was on the way to a Sure Start programme. She and I—when she was the first designated Public Health Minister and I had education and employment—started the Sure Start programme. We both went on a journey through to Cabinet—she exemplified her own wonderful networking skills in helping us to win the Olympics for London and their implementation, which shone across the world, and I had all sorts of different guises, good and bad. That journey has, for Tessa, my noble friend, always been about support, care and reaching out to others. When terrible terrorist attacks have taken place, not just here but across the world, she has cared about those families, just as her family now care about her. We are, all of us, privileged to be here this afternoon and to have heard her speak. She has given us a clarion call to pick up that cudgel and work tirelessly to ensure that what she seeks is carried forward for others in the future, and that our NHS, our scientists, our innovators and our consultants can draw down on the experience from across the world and can remember Tessa Jowell as we all will, and who we are privileged to have heard this afternoon.

NHS: Sustainability and Transformation Plans

Lord Blunkett Excerpts

Monday 20th March 2017 Lords Chamber

[Lord O’Shaughnessy]

I am sorry to hear the noble Baroness say that about the STPs, which have received support from the King’s Fund and NHS clinical commissioners. I hope that she is also aware that in the Budget the Chancellor announced £325 million of capital spending to support the strongest STPs, those which are capable of providing the kind of integration she has talked about and are delivering the highest levels of performance.

[Lord Blunkett (Lab)]

My Lords, will the Minister share with us whether the department has provided advice or best practice in the localities on the first test of the service reconfiguration? A great deal of disquiet has emerged about a lack of engagement of key partners, never mind mobilising the support of the wider community.

[Lord O’Shaughnessy]

The noble Lord is quite right to bring up the issue of engagement. Those STPs which have been completed and published in draft form are now going through the engagement process. They are also being stress tested by NHS England and NHS Improvement to provide exactly the kind of scrutiny that he has talked about. Finally, in addition to the tests I have mentioned, there can be no significant service reconfigurations or bed closures without passing those tests and without public consultation to provide precisely the reassurance that these changes are about delivering national standards—they are not about trying to find a way around them.

Pregnancy: Neural Tube Defects

Lord Blunkett Excerpts

Monday 21st December 2015 Lords Chamber

[Lord Prior of Brampton]

My Lords, I am certainly not going to argue on clinical grounds with the noble Lord, who knows far more about this than I do. However, the issues are not purely clinical; they are to do with the mass medication of the whole population to reach a very small minority of women of child-bearing age. There are also some administrative issues to do with making sure that people do not take too much folic acid, as some cereals have folic acid added to them. However, I understand exactly what the noble Lord is saying, and can only repeat that the Minister for Public Health is reviewing this now.

[Lord Blunkett (Lab)]

Can I surprise the Minister and not necessarily upset my noble friend Lord Rooker, but put down a word of caution? I agree with what the Minister has just said about having great caution when we involve ourselves in any mass medication—I have a history of being awkward on these issues, including mass medication through the water supply. I have no doubt whatsoever that this is an effective way of tackling the problem, but I have every concern that it is a slippery slope that we go down with great care.

[Lord Prior of Brampton]

My Lords, I think they were helpful and wise words from the noble Lord, Lord Blunkett. This is a difficult issue, and it is not as black and white as is sometimes portrayed. As I said, my honourable friend in the other House is taking all these matters into consideration.

Oral Answers to Questions

Lord Blunkett Excerpts

Tuesday 12th July 2011 Commons Chamber

[Mr Lansley]

The House will know of my hon. Friend’s consistent support, through the all-party group, for patients with cancer. I entirely agree that a number of proxy measures and process measures will be relevant in the context of the commissioning outcomes framework. There may be measures that are attributable to CCGs individually in some respects. For example, the quality of life of people living with long-term conditions, to which I referred, would be relevant to a small population. For other measures, however, it may be appropriate for the CCGs to be held to account at the level of, for example, a cancer network, using cancer registry data.

[Mr David Blunkett (Sheffield, Brightside and Hillsborough) (Lab)]

The considerable improvement and focus on breast, lung and bowel cancer is very welcome, but groups campaigning on prostate and ovarian cancer are extremely worried about both the lack of update guidance and the failure to reverse premature death, especially in ovarian cancer, over the last 30 years. Has the Secretary of State anything new to tell us about the direction in these areas?

[Mr Lansley]

The right hon. Gentleman will doubtless be aware that we published a quality standard for ovarian cancer, and that the Minister of State, Department of Health, my hon. Friend the Member for Sutton and Cheam (Paul Burstow), published the outcomes strategy for cancer, which will have been relevant to many of the issues to which the right hon. Gentleman refers. I continue to look forward to the results of a major trial on screening for ovarian cancer, but I am afraid that I anticipate that we shall not be able to see the results and recommendations for nearly three years.

Reform of Social Care

Lord Blunkett Excerpts

Monday 4th July 2011 Commons Chamber

[Mr David Blunkett (Sheffield, Brightside and Hillsborough) (Lab)]

As a vice-president of the Alzheimer’s Society, and like many hon. Members, I am aware that it is dementia awareness week. The most enormous resource is needed to help both individuals and their carers, particularly with residential support. Is not my hon. Friend the Member for Sheffield, Heeley (Meg Munn) entirely right to draw attention to the fact that even within Andrew Dilnot’s acknowledgement of the perverse incentives, there is still an emphasis on the care market and the drive to encourage people to take up, or to consider the option of, residential care? Do we not need to put the glue back by supporting families and neighbourliness, so that we can keep people independent in their own homes as long as is humanly possible?

[Mr Lansley]

I understand the point that the right hon. Gentleman makes and in the past some of the criticisms of previous proposals have been made because they would have led to a situation in which informal care and family care would not have been properly supported—indeed, there would have been perverse incentives for people not to have family carers. We need to support family carers rather than bypass them.

I am glad that the right hon. Gentleman raises the issue of dementia. It is tremendously important that we understand it is one of the principal reasons for such a rising burden of disability and requirement for care and support. It is why we are looking to the longer term, not least to improve research into dementia. I am grateful to the Minister of State, my hon. Friend the Member for Sutton and Cheam, who has chaired the work on research into dementia, and he was able to announce substantial additional funding to support dementia research just the week before last.